Illumina Accelerator Welcomes First Global Cohort of Genomics Startups
Retrieved on:
Tuesday, June 23, 2020
Other Health, Pharmaceutical, Research, Baby, Maternity, Oncology, Software, Medical devices, Infectious diseases, Consumer, Genetics, Science, Technology, Clinical trials, Cardiology, Biotechnology, Agriculture, AIDS, Natural Resources, Health, Business incubators, DNA sequencing, Illumina, Inc., Microarrays, Startup accelerator, Startup company, Companies, Branches of biology, Biotechnology, Illumina Accelerator, Illumina
Illumina, Inc. (NASDAQ:ILMN) has selected seven early-stage companies to join the first global cohort of Illumina Accelerator, the company creation engine focused on partnering with entrepreneurs to build breakthrough genomics startups.
Key Points:
- Illumina, Inc. (NASDAQ:ILMN) has selected seven early-stage companies to join the first global cohort of Illumina Accelerator, the company creation engine focused on partnering with entrepreneurs to build breakthrough genomics startups.
- As we navigate the current global pandemic, there is an even stronger urgency to create breakthrough genomics startups that will transform human health and beyond, said Amanda Cashin, Co-founder and Global Head of Illumina Accelerator.
- Illumina Accelerator is the worlds first business accelerator focused solely on creating an innovation ecosystem for the genomics industry.
- Since launching in 2014, Illumina Accelerator has invested in 45 genomics startups from across the globe, which have collectively raised approximately $400 million in venture capital funding.